Clinical effect of fluticasone salmeterol powder for inhalation in treatment of patients with cough variant asthma
10.3969/j.issn.1005-1678.2016.04.19
- VernacularTitle:氟替卡松沙美特罗粉吸入剂治疗咳嗽变异型哮喘疗效研究
- Author:
Qi ZHANG
;
Feng TAO
- Publication Type:Journal Article
- Keywords:
fluticasone/salmeterol;
cough variant asthma;
fractional exhaled nitric oxide;
cough symptom score
- From:
Chinese Journal of Biochemical Pharmaceutics
2016;36(4):69-70,73
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy of seretide (fluticasone/salmeterol) in treatment of patients with cough variant asthma(CVA). Methods 86 CVA patients were treated with fluticasone/salmeterol propionate 8 weeks, after 8 weeks, 86 patients were randomly assigned to treatment group and control group, each group with 43 patients, the treatment group continued medicine for 4 weeks, the control group without any treatment.The two groups of patients FENO measurement values, cough symptom score before treatment and after treatment for 8 weeks, 12 weeks were compared. Results After treatment for 8 weeks, cough symptom scores and FeNO in the two groups values decreased significantly compared with those before treatment(P<0.05), 12 weeks after treatment, treatment group cough product, FeNO values, were lower than in control group(P<0.05).Conclusion Fluticasone salmeterol powder inhalation can effectively improve the symptoms of cough cough variant asthma.Symptom score and FENO value can be used as a monitoring index to evaluate the therapeutic effect of CVA, and the FENO value is more effective, which has the advantages of non-invasive, simple, safe, rapid and repeatable.
